This is the reality that Wall Street or our ASX put the market cap on the outcome of this trail as we know Ryoncil alone would be valued msb at around $3, as mentioned by many knowledgeable posters here and the successful rate of Ryoncil would be over 95% by now.
I like to quote from A Murray Capital:
"MSB is currently pursuing a BLA approval in the USA which is very different from a normal FDA approval and 90% of BLA applications are approved. The fact the product was approved in Japan first which has an even harder regulatory framework to me shows the US BLA application is lower risk than the market seems to perceive. Remember there is no current approved product in the USA for children under 12 years and the only treatment for adults has shocking side effects that nobody on this email list would want to have."
Glta
Cell Therapy News/Articles, page-3714
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.78 |
Change
0.255(16.7%) |
Mkt cap ! $2.032B | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.83 | $1.71 | $27.76M | 15.59M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30000 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 48074 | 4 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |